Elevai Labs announced the appointment of Orian Shirihai, MD, PhD, to the Scientific Advisory Board of its subsidiary, Elevai Biosciences. As a renowned researcher in the field of metabolism, Dr. Shirihai will support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAB:
- Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
- ELEVAI Labs Shares Future Direction and Financial Outlook
- Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line
- Elevai Labs subsidiary announces Elevai S-Series hair, scalp care
- ELEVAI Labs Announces CEO Transition and Executive Restructuring